Ventricular Tachycardia (VT) Ablation or Escalated Drug Therapy

PHASE4CompletedINTERVENTIONAL
Enrollment

260

Participants

Timeline

Start Date

May 31, 2009

Primary Completion Date

December 31, 2015

Study Completion Date

December 31, 2015

Conditions
Recurrent Ventricular Tachycardia
Interventions
PROCEDURE

Catheter Ablation

Intracardiac electrode catheters are placed via central vasculature to identify myocardial scar, and surviving conduction channels within the scar which form the substrate for ventricular tachycardia. Radiofrequency energy is applied to these sites, interrupting the VT circuits.

DRUG

Escalated Antiarrhythmic Therapy

"Patients who have 'failed' antiarrhythmic therapy (except amiodarone) will be prescribed: Amiodarone 400 mg twice daily for 2 weeks, followed by 400 mg/day for 4 weeks, followed by 200 mg/day thereafter.~Patients who 'failed' amiodarone (less than 300mg/day) will be prescribed: Amiodarone 400 mg three times a day for 2 weeks, followed by 400 mg/day for 1 week and 300 mg/day thereafter.~Patients who 'failed' amiodarone (greater or equal to 300mg/day) will be prescribed: Amiodarone at the current dose with the addition of mexiletine 400 to 800 mg/day"

Trial Locations (1)

B3H 3A7

QEII Health Sciences Centre, Halifax

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Abbott Medical Devices

INDUSTRY

collaborator

Biosense Webster, Inc.

INDUSTRY

collaborator

Canadian Institutes of Health Research (CIHR)

OTHER_GOV

lead

John Sapp

OTHER

NCT00905853 - Ventricular Tachycardia (VT) Ablation or Escalated Drug Therapy | Biotech Hunter | Biotech Hunter